EmbracePlus, Care App and Aura Usability Study

Sponsor
Empatica, Inc. (Industry)
Overall Status
Completed
CT.gov ID
NCT04807608
Collaborator
United States Department of Defense (U.S. Fed)
335
1
12
27.9

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the usability of the system which includes the wearable device, app and cloud data processing, including an algorithm (Aura) capable of detecting possible early signs of respiratory infections in healthy individuals.

In addition, the investigators would like to evaluate the presence of any allergic reactions to materials used in the manufacture of the EmbracePlus.

Condition or Disease Intervention/Treatment Phase
  • Other: Usability Assessment

Detailed Description

The investigators wish to evaluate of the usability, according to the requirements of IEC 62366-1:2015/AMD 1:2020 of a wearable device - EmbracePlus, the Empatica Care app and Aura algorithm, an early-warning wearable/AI platform for alerting to COVID-19 and other possible respiratory infections before a person is symptomatic. The system consists is a smartwatch coupled with an AI algorithm (Aura) developed by Empatica. The Aura algorithm analyzes physiological signals and derived biomarkers (such as sleep patterns) in order to detect possible early signs of respiratory infection. It has been originally developed by Empatica, validated with influenza and rhinovirus data and is being currently validated for COVID-19 infections.

Study Design

Study Type:
Observational
Actual Enrollment :
335 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Study for the Evaluation of the Usability of EmbracePlus, Empatica Care Platform and Aura Algorithm
Actual Study Start Date :
May 31, 2021
Actual Primary Completion Date :
May 31, 2022
Actual Study Completion Date :
May 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Healthy Users

Each subject will be provided with a wearable device (smartwatch EmbracePlus manufactured by Empatica), to be worn every day outside of work hours for a total of 6 weeks. After the 6 weeks of data collection the participant will be asked to fill an online questionnaire related to the system usability (max 20 min).

Other: Usability Assessment
A survey will be administered to the subject at the end of the 6th week of product usage related to the wearable device and the related software platform's usability. Survey items will include both Likert-scale items that will be analyzed quantitatively and open-ended feedback that will be summarized qualitatively.

Outcome Measures

Primary Outcome Measures

  1. EmbracePlus, Care App and Aura Usability: Based on user survey [After 6 weeks of system usage]

    Determine the ease of use of the system composed of EmbracePlus, Care app and Aura algorithm and user satisfaction, by means of a survey items that include both Likert-scale items that will be analyzed quantitatively and open-ended feedback that will be summarized qualitatively.

  2. EmbracePlus, Care App and Aura safety: total number (%) of AEs and SAEs [After 6 weeks of system usage]

    The second primary endpoint will be the total number (%) of AEs and SAEs related to the device use

Secondary Outcome Measures

  1. EmbracePlus, Care app and Aura reliability with different smartphones [Single-point evaluation (baseline)]

    Evaluate the reliability of the system with different brands and models of smartphone by means of participants reported bugs and problems

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Age: Participants must be between the ages of 18-99

  2. Gender: No restrictions

  3. Disease: healthy participants

  4. Adult participant must either be able to give consent

  5. Participants must be fluent in the language of the consent forms (Currently limited to English).

  6. Participants must reside in the United States.

  7. Participants should have a physical home address where they can receive the device

  8. Participants must have a personal smartphone Apple or Android (at least iPhone 8 or Android 5.0)

Exclusion Criteria:
  1. Participants must not have broken or injured skin at the wrist where EmbracePlus is worn, and they must be able to tolerate wearing EmbracePlus snugly for long periods of time. Thus, they should not have allergies to the material composition of the EmbracePlus smartwatch, or discomfort wearing a smartwatch during the night.

  2. Participants are not willing to wear the device during nighttime

  3. Participants should not have pre-existing cardiovascular disease or respiratory disease

  4. Participants must not be pregnant or planning to become pregnant within two months at the time of screening

Contacts and Locations

Locations

Site City State Country Postal Code
1 Empatica Inc Boston Massachusetts United States 02108

Sponsors and Collaborators

  • Empatica, Inc.
  • United States Department of Defense

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Empatica, Inc.
ClinicalTrials.gov Identifier:
NCT04807608
Other Study ID Numbers:
  • 2021-001
First Posted:
Mar 19, 2021
Last Update Posted:
Jun 2, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Empatica, Inc.

Study Results

No Results Posted as of Jun 2, 2022